AURA - Aura Biosciences, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$17.50
DETAILS
HIGH:
$18.00
LOW:
$17.00
MEDIAN:
$17.50
CONSENSUS:
$17.50
UPSIDE:
186.89%
About Aura Biosciences, Inc. (https://www.aurabiosciences.com)
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Jill Hopkins | Chief Medical Officer & President of Research and Development | 1965 | $792,750 USD |
| Susan Abu-Absi | Chief Operating Officer | – | $592,500 USD |
| Alex Dasalla | Head of Investor Relations & Corporate Communications | – | – |
| Amy Elazzouzi | Senior Vice President of Finance, Treasurer and Secretary | 1974 | – |
| Anthony Daniels | Vice President & Therapeutic Area of Head Ocular Oncology | – | – |
| Erica Kratz | Chief Regulatory & Quality Officer | – | – |
| Joe McQuaid | VP & Therapeutic Area Head of Urologic Oncology | – | – |
| Julie Person | Chief People Officer | 1974 | – |
| Natalie C. Holles | President, CEO & Director | 1973 | – |
| Patrick Nealon | Senior Vice President of Clinical Development Operations | – | – |